|
業務類別
|
Biotechnology |
|
業務概覽
|
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat. |
| 公司地址
| 10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121 |
| 電話號碼
| +1 858 727-1755 |
| 傳真號碼
| +1 310 358-3209 |
| 公司網頁
| https://www.capricor.com |
| 員工數量
| 160 |
| Dr. Linda Marban, PhD |
President, Chief Executive Officer and Director |
美元 300.00K |
10/04/2026 |
| Mr. Anthony J. Bergmann, M.B.A. |
Chief Financial Officer and Principal Accounting Officer |
美元 425.00K |
10/04/2026 |
| Ms. Karen G. Krasney, J.D. |
Executive Vice President and General Counsel |
美元 391.77K |
10/04/2026 |
|
|
| Dr. Philip J. Gotwals, PhD |
Independent Director |
10/04/2026 |
| Mr. David B. Musket |
Independent Director |
10/04/2026 |
| Dr. Frank Litvack,M.D. |
Executive Chairman of the Board |
10/04/2026 |
| Mr. George W. Dunbar,Jr |
Independent Director |
10/04/2026 |
| Mr. Michael Kelliher |
Independent Director |
10/04/2026 |
| Dr. Linda Marban, PhD |
President, Chief Executive Officer and Director |
10/04/2026 |
| Dr. Paul Gisbert Auwaerter, M.B.A.,M.D. |
Independent Director |
10/04/2026 |
| Ms. Karimah Es Sabar |
Independent Director |
10/04/2026 |
|
|
|
|
